NSE: MANKIND · 28 October 2026
- Mankind Pharma has risen 12.53% over 3 trading sessions; today's move is -0.51%.
- Mankind Pharma reported consolidated revenue from operations of ₹4,338 crore for the second quarter ended September 30, 2026, marking a 17.3% year-on-year increase. EBITDA grew 27.2% to ₹1,175 crore with margins expanding 210 basis points to 27.1%, while profit after tax surged 37.7% to ₹716 crore. Domestic business (excluding consumer healthcare) grew 15.9% year-on-year, supported by outperformance in chronic and acute therapeutic segments.
- Trading volume was 1.33 times the 20-day average daily volume.
Mankind Pharma share price: 12.53% rise over 3 trading sessions
Mankind Pharma Limited shares declined by 0.51% on Tuesday, closing at ₹2,489.80 after moving between an intraday high of ₹2,549.00 and a low of ₹2,478.50.
The broader market exhibited mild weakness, with the Nifty index slipping 0.22%, whereas the Nifty Pharma sector index rose by 1.04%. Despite the sector-wide gains, Mankind Pharma underperformed its immediate peers for the session following strong recent outperformance, where the stock had gained 8.24% in the prior trading session and 13.10% over the last two trading days.
The recent price action follows the company's Q2 and H1 FY27 financial results released on October 26, 2026, which reported a 17.3% year-on-year increase in revenue from operations to ₹4,338 crore and a 37.7% growth in profit after tax to ₹716 crore. While the strong operational numbers provide fundamental context, today's modest pullback appears to reflect profit-taking after sharp gains over preceding sessions rather than any new negative catalyst.
10.44 lakh shares traded by 28 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 7.84 lakh shares (1.33 times). The five-day average daily volume was 11.26 lakh shares. Separately, the NSE report for 27 October 2026 showed 6.78 lakh shares delivered, representing 22.38% of that day’s traded volume. The same report recorded 112,506 trades.
The modest decline of 0.51% follows sharp back-to-back gains of 8.24% in the prior session and 13.10% over two sessions, pointing to natural profit-taking following recent strength rather than any specific negative trigger.
Latest Company Developments
Mankind Pharma reported consolidated revenue from operations of ₹4,338 crore for the second quarter ended September 30, 2026, marking a 17.3% year-on-year increase. EBITDA grew 27.2% to ₹1,175 crore with margins expanding 210 basis points to 27.1%, while profit after tax surged 37.7% to ₹716 crore. Domestic business (excluding consumer healthcare) grew 15.9% year-on-year, supported by outperformance in chronic and acute therapeutic segments.
Strong quarterly earnings growth and margin expansion directly validate the company's specialty portfolio strategy and operational efficiency.
The company announced a strategic agreement to acquire a majority stake in Armed Cell Therapeutics, marking its entry into next-generation CAR-T therapies. The transaction aims to enhance Mankind's advanced R&D capabilities in oncology and cell-based treatments.
This strategic acquisition expands the company's technological footprint into advanced biotherapies and next-generation oncology treatments.
Mankind Pharma released detailed presentation slides for its analyst and institutional investors meet following the Q2 financial results. The presentation outlined strategic pillars including chronic segment expansion, hospital business growth, and brand scaling initiatives.
Provides institutional investors and analysts with granular insights into therapeutic segment performance and long-term capital allocation plans.
a press release dated October 26, 2026, titled "Press Release on Financial Results for Q2 & H1 FY27".
a press release dated October 15, 2026, titled "Press Release titled Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies ".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 11.31% on 30 September 2026. This compares with 10.87% on 30 June 2026, a change of +0.44 percentage points.
The filing reported 36 MF/UTI holders.
What to Watch Next
- Execution progress and integration timelines regarding the Armed Cell Therapeutics acquisition for next-generation CAR-T therapies
- Sustained growth momentum in key domestic chronic therapy segments such as cardiac and anti-diabetes
- Performance of consumer healthcare recovery in domestic urban and rural retail channels
- Volume and delivery trends relative to the 20-day average volume of 1,044,410 shares
Other Dated Coverage
- Mankind Pharma Share Price Today: Rises 13.10% in 2 Trading Sessions | 27 October 2026 — 27 October 2026
- Mankind Pharma Share Price Today: Why MANKIND Is Rising 4.49% | 26 October 2026 — 26 October 2026
- Mankind Pharma Share Price Today: Why MANKIND Is Falling 2.77% | 23 October 2026 — 23 October 2026
More Mankind Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Mankind Pharma company news?
Mankind Pharma reported consolidated revenue from operations of ₹4,338 crore for the second quarter ended September 30, 2026, marking a 17.3% year-on-year increase. EBITDA grew 27.2% to ₹1,175 crore with margins expanding 210 basis points to 27.1%, while profit after tax surged 37.7% to ₹716 crore. Domestic business (excluding consumer healthcare) grew 15.9% year-on-year, supported by outperformance in chronic and acute therapeutic segments.
How strong was Mankind Pharma’s trading volume?
10.44 lakh shares traded, 1.33 times the 20-day average daily volume. The price and volume data are dated 28 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.